- Record: found
- Abstract: found
- Article: not found
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
Anne de la Rochefordiere
1 ,
Maud Kamal
1 ,
Anne Floquet
2 ,
Laurence Thomas
2 ,
Peter Petrow
1 ,
Thierry Petit
3 ,
Marius Pop
3 ,
Michel Fabbro
4 ,
Christine Kerr
4 ,
Florence Joly
5 ,
Emmanuel Sevin
5 ,
Sophie Maillard
6 ,
Hervé Curé
6 ,
Béatrice Weber
7 ,
Claire Brunaud
7 ,
Mathieu Minsat
8 ,
Laurence Gonzague
8 ,
Dominique Berton-Rigaud
9 ,
Maud Aumont
9 ,
Laurence Gladieff
10 ,
Karine Peignaux
11 ,
Virginie Bernard
1 ,
Quentin Leroy
1 ,
Ivan Bieche
1 ,
Audrey Margogne
1 ,
AnaTereza Nadan
1 ,
Virginie Fourchotte
1 ,
Alhassane Diallo
1 ,
Benard Asselain
1 ,
Corine Plancher
1 ,
Sébastien Armanet
1 ,
Philippe Beuzeboc
1 ,
Suzy M Scholl
12
Jun 01 2015
Read this article at
ScienceOpenPublisherPubMed
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcinoma limited to the pelvis.